Levomilnacipran – Kodiac biolabs

Plain-language summaryIntrigue 54 / 100

Levomilnacipran (Fetzima) is one mirror-image half of milnacipran, sold separately by Forest Pharmaceuticals in the US after FDA approval in 2013. It is unusual among SNRIs because it preferentially blocks the norepinephrine pump rather than the serotonin one, which is the opposite of duloxetine and venlafaxine. That noradrenergic emphasis was meant to deliver stronger effects on energy, motivation, and concentration in depressed patients. Trial data are favorable but not overwhelming, and the drug never gained the prescribing momentum of duloxetine. The parent compound milnacipran (the racemic mix) is widely used in Europe and Japan for depression and is approved in the US specifically for fibromyalgia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

A clean NET-selective SNRI probe with solid approval data and low novelty

Look, there are worse compounds to have in a library than levomilnacipran, but lets be direct: the SNRI class in 2026 is not where you go to find frontier pharmacology. Duloxetine, venlafaxine, desvenlafaxine — the space is crowded, mature, and the clinical effect sizes in MDD are modest across the board. What levomilnacipran does have, and what keeps it from being completely unremarkable, is its inverted selectivity. NET affinity at roughly 11 nM beats SERT at roughly 19 nM, which is the opposite of every other major SNRI on the market. That matters when youre trying to dissect norepinephrine versus serotonin contributions to an effect in a rodent model or a mechanistic human study.

The pharmacokinetic profile is genuinely clean. Mostly renal excretion, minimal CYP3A4 metabolism, near-zero off-target activity at adrenergic, dopaminergic, muscarinic, or histaminergic receptors. For pharmacology work where you want to isolate transporter blockade without confounding receptor hits, thats useful. Its the closest thing to a reference standard NET-preferring SNRI the field has, which is a narrow but real distinction.

Where it scores poorly is novelty and mechanism promise. The compound was approved by the FDA in 2013. Thats not a criticism — FDA approval means real phase 3 evidence, which the evidence and translational scores reflect — but it does mean the interesting questions have mostly been asked. If you want to understand NE reuptake inhibition in the clinic, the semaglutide-equivalent paradigm shift moment for SNRIs never arrived, and levomilnacipran didnt change that. We think the research attention it still generates is almost entirely as a comparator or a probe, not because anyone expects a surprise finding from the compound itself.

Honestly, the differentiation score is the most interesting conversation. Reboxetine is more NET-selective, but reboxetine has a problematic efficacy record in humans and regulatory problems in the US. Atomoxetine is NET-selective but carries pediatric ADHD baggage that complicates off-label use in adult neuropsychiatric research. Levomilnacipran sits in the middle: approved, clean, accessible, usable. For a lab running a study on noradrenergic contributions to cognitive function or pain modulation, it is probably the reference arm you reach for. Thats worth something. Its just not worth a lot in 2026 when the real action in CNS pharmacology is happening at psychoplastogen, kinase modulator, and mitochondrial peptide addresses.

If your program specifically needs a NET-biased SNRI with a clean off-target profile and real human pharmacokinetic data, levomilnacipran earns its shelf space. For anyone else, it sits comfortably in the established-mature tier: competent, useful in the right context, and not a reason to change your research agenda.

Novelty: 22
Mechanism promise: 35
In-category differentiation: 48
Evidence quality: 72
Translational signal: 65
Research bench value: 58

Rationale Approved in 2013 with a real clinical evidence base, levomilnacipran earns credit for NET > SERT selectivity as a research tool, but the SNRI class is deeply mature and the compound itself introduces no new mechanism. Evidence and translational scores pull the overall up from what its novelty and mechanism scores deserve; bench value is legitimate but limited to NE/SERT dissection work.

Pure SNRI ((1S,2R)-enantiomer)

The (1S,2R)-enantiomer of milnacipran; a pure SNRI with strong NET selectivity over SERT and minimal off-target activity.

Abstract

Levomilnacipran ((1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; CAS 96847-55-1 (HCl salt); molecular formula C15H22N2O; molecular weight 246.35) is the (1S,2R)-enantiomer of milnacipran, marketed as Fetzima by Forest Pharmaceuticals after FDA approval in 2013. Distinct among SNRIs for inverse selectivity: NET affinity (Ki approximately 11 nM) exceeds SERT affinity (Ki approximately 19 nM) by approximately 2-fold, the opposite of duloxetine and venlafaxine. The compound has minimal off-target activity at adrenergic, dopaminergic, muscarinic, or histaminergic sites. Plasma half-life is approximately 12 hours; metabolism is primarily renal (excreted unchanged) with minor CYP3A4 contribution, producing minimal drug-drug interaction potential. Approved for major depressive disorder; off-label investigation in attention deficit and chronic pain conditions. The dosing form is extended-release; 40 to 120 mg once daily. Used as the reference NET-selective SNRI in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-213Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.